Abstract
Objective The aim of this was to assess the short-term impact of the pandemic on non-COVID-19 patients living in a one-million inhabitants area in Northern Italy (Bologna Metropolitan Area-BMA), analyzing time trends of Emergency Department (ED) visits, hospitalizations and mortality.
Methods We conducted a retrospective observational study using data extracted from BMA healthcare informative systems. Weekly trends of ED visits, hospitalizations, in- and out-of-hospital, all-cause and cause-specific mortality between December 1st, 2019 to May 31st, 2020, were compared with those of the same period of the previous year, using Joinpoint regression models and incidence rate ratios.
Results Non-COVID-19 ED visits and hospitalizations showed a stable trend until the first Italian case of COVID-19 has been recorded, on February 19th, 2020, when they dropped simultaneously. The reduction of ED visits was observed in all age groups and across all severity and diagnosis groups. In the lockdown period a significant increase was found in overall out-of-hospital mortality (43.2%) and cause-specific out-of-hospital mortality related to neoplasms (76.7%), endocrine, nutritional and metabolic (79.5%) as well as cardiovascular (32.7%) diseases.
Conclusions The pandemic caused a sudden drop of ED visits and hospitalizations of non-COVID-19 patients during the lockdown period, and a concurrent increase in out-of-hospital mortality mainly driven by deaths for neoplasms, cardiovascular and endocrine diseases. The findings of this study might be useful to understand both the population reaction and the healthcare system response at the early phases of the pandemic in terms of reduced demand of care and systems capability in intercepting it.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study received no specific funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Emilia Romagna Ethical Committee on August 3rd, 2020.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
lucasanti{at}hotmail.it, davide.golinelli{at}unibo.it, a.tampieri{at}ausl.imola.bo.it, gabriele.farina{at}aosp.bo.it, manfredi.greco{at}studio.unibo.it, simona.rosa{at}unibo.it, michellebeleffi{at}gmail.com, biavati.bianca{at}gmail.com, campinotifrancesca{at}gmail.com, stefania.guerrini{at}aosp.bo.it, r.ferrari{at}ausl.imola.bo.it, paola.rucci2{at}unibo.it, mariapia.fantini{at}unibo.it, fabrizio.giostra{at}aosp.bo.it
Data Availability
The data used in the study are controlled by a third party, two public health authorities (Local Health Authority of Bologna and Local Health Authority of Imola), and cannot be shared publicly. However, aggregated and anonymized data are available upon specific request to the corresponding authors. Interested researchers can replicate our study findings by contacting the authors or the Local Health Authorities of Bologna Metropolitan Area (AUSL Bologna and AUSL Imola).
